We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.025 | -1.13% | 2.18 | 2.11 | 2.25 | 2.24 | 2.20 | 2.20 | 816,884 | 16:35:29 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -1.96 | 7.47M |
Date | Subject | Author | Discuss |
---|---|---|---|
13/4/2022 13:31 | And it is worth noting the company didn't bother to tell the shareholders what the half-life, bioavailability and other PK parameters are. Why not I wonder... | nobbygnome | |
13/4/2022 13:28 | Hello Eva. As you know I talk about the science and the regulatory process. The FDA have not yet approved the phase III to go ahead. If they do, the price will go up and if they don't, it will plummet. | nobbygnome | |
13/4/2022 13:26 | Peeps pumping this on twitter, advfn are still down on this and desperately trying for this to go above 10p!! | daar | |
13/4/2022 13:25 | And where is my friend Nobby ? Oh wait - his beloved SNG crashed and this dog going up.. Well... | eva_1989 | |
13/4/2022 13:24 | Nice job Mr. Tim - One more jump and I will get my average price. With money in the bank and offering at premium of 11P, I can see this cross 11P for sure.. For me, If I'm new investor then there is no risk of further dilution for 1+ year and once we get approval from FDA then bye bye sub 10P. Still think today price should go further north of 10P | eva_1989 | |
13/4/2022 13:24 | Bit of an exaggeration. | arlington chetwynd talbott | |
13/4/2022 13:10 | Going orbital boys. | firestorm911 | |
13/4/2022 13:09 | Possibly double figures today - a lot of sellers taken out - | tomboyb | |
13/4/2022 13:07 | Interesting to look back:https://www.ii. | arlington chetwynd talbott | |
13/4/2022 13:03 | How come such precision, firestorm? | aimingupward2 | |
13/4/2022 12:35 | Depends how quickly they can deliver the Phase 3 roadmap. If "in due course" means it all goes quiet for a bit, this could well drift lower. But if they keep the momentum going with more RNSs in the coming weeks, 8p could look like a decent entry point. | arlington chetwynd talbott | |
13/4/2022 11:44 | I think the market cap looks too low - accumulate - | tomboyb | |
13/4/2022 11:39 | I took one-sixth off the table at 9p early doors, not sure if BB ramping alone is going to get this into double figures but happy to take more off the table if it does. | arlington chetwynd talbott | |
13/4/2022 11:20 | Money is on here. Filter applied. Dddd has just dropped back. It is being p and d all over advfn. It is a very good company though. This share is far more active.. | bobdown2 | |
13/4/2022 11:15 | DDDD is stuck on the EMA100, expect yanks to wake this up this afternoon. | albert arthur | |
13/4/2022 11:00 | This level feels about right for now - a Phase 3 roadmap RNS may be necessary for further progress. | arlington chetwynd talbott | |
13/4/2022 10:26 | Cooked here. 4D breaking out. | tidy 2 | |
13/4/2022 10:10 | 60% premium is a lot of wonga, what do they know that we do not know? Watching with interest here. | fanny smacker | |
13/4/2022 10:05 | Thanks, Babbler, did not know they paid a 60% premium. | me ole china | |
13/4/2022 09:51 | the Placing was at a 60% premium. | babbler | |
13/4/2022 09:44 | very significant outcome for IMM -looks like shorters are getting desperate, well done holders here with that announcement | pre | |
13/4/2022 09:40 | Fannies will be getting smacked here, but the end of tomorrow's back to sub 6p. Trial at least end of this year, or Q1 2023. where do they get the 10m they need? | fanny smacker |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions